반응식
[F:1][C:2]1[CH:7]=[C:6]([F:8])[CH:5]=[CH:4][C:3]=1[C@:9]1([C@@H:12](O)[CH3:13])[CH2:11][O:10]1.[CH3:15][O:16][C:17]1[N:25]=[CH:24][N:23]=[C:22]2[C:18]=1[NH:19][CH:20]=[N:21]2.FC1C=C(F)C=CC=1[C@]1([C@H](N2C3C(=NC=NC=3OC)N=C2)C)CO1>>[F:1][C:2]1[CH:7]=[C:6]([F:8])[CH:5]=[CH:4][C:3]=1[C@:9]1([C@H:12]([N:21]2[CH:20]=[N:19][C:18]3[C:22]2=[N:23][CH:24]=[N:25][C:17]=3[O:16][CH3:15])[CH3:13])[CH2:11][O:10]1참가 물질
4
실험 절차
Using (1S)-1-[(2R)-2-(2,4-difluorophenyl)-2-oxiranyl]ethanol (523 mg) and 6-methoxypurine 1/2 hydrate (415 mg), (2S)-2-(2,4-difluorophenyl)-2-[(1R)-1-[6-methoxy-7(7H)purinyl]ethyl]oxirane (205 mg) and (2S)-2-(2,4-difluorophenyl)-2-[(1R)-1-[6-methoxy-9(9H)-purinyl]ethyl]oxirane (183 mg) were obtained as a white powder respectively by the same way as in Reference Example 2.
출처 및 근거
- ORD 기록
- ord-cf7180fde80649579b3443b9df903eff
- 출처 데이터셋
- uspto-grants-1996_02
- 특허 번호
- US05495024
연결된 노트
불러오는 중…